Twist Biopharma Implements Genedata Biologics to Advance Synthetic Biology-driven Antibody Discovery
First-in-class software platform digitalizes Twist Biopharma’s innovative antibody lead identification and optimization
"Using our proprietary DNA synthesis technologies, we are unlocking new sources of molecular diversity to help our customers engineer novel and truly innovative therapeutic antibodies," said
Genedata Biologics will be used to enable high-throughput, high-quality biophysical characterization of high-aﬃnity, functional fully human IgG and single domain antibodies, with a focus on difficult target classes, such as GPCRs. Genedata Biologics will be fully integrated with Twist’s proprietary technology platform for lead identification and optimization, including Twist proprietary human antibody phage display libraries, Twist Antibody Optimization (TAO) platform for affinity/developability maturation, affinity binding assays, analytical/developability assessment, receptor-ligand assays, in vitro functional assays and CHO stable pool generation to enable predevelopment activities.
For more than 20 years, Genedata has been leading the digitalization of R&D and is the predominant platform used by global biopharma giants such as Pfizer, Janssen,
“Twist Biopharma is leading the way in industrializing synthetic biology and we are thrilled that they have chosen Genedata to make the most of their technology for next-generation biopharma R&D,” said
Meet Twist and Genedata at PEGS Europe:
“Synthetic DNA Technologies Enable Antibody Discovery and Optimization”
“Industrializing IO Therapeutic Discovery Platforms: Multispecifics, Engineered TCRs and CAR Ts”
“A Platform Approach to Manage Developability and Manufacturability Risks of Biologics Molecules”
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI in their R&D, spanning early discovery all the way to the clinic. Founded in 1997, Genedata is headquartered in
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
+1 212 600 1902
+1 925 202 6211
Phone: +41 61 511 85 61